Detection of ERBB2 amplification in uterine serous carcinoma by next-generation sequencing: an approach highly concordant with standard assays
- PMID: 33077919
- DOI: 10.1038/s41379-020-00695-5
Detection of ERBB2 amplification in uterine serous carcinoma by next-generation sequencing: an approach highly concordant with standard assays
Abstract
Uterine serous carcinoma is an aggressive subtype of endometrial cancer that accounts for fewer than 10% of endometrial carcinomas but is responsible for about half of deaths. A subset of cases has HER2 overexpression secondary to ERBB2 gene amplification, and these patients may benefit from anti-HER2 therapies, such as trastuzumab. HER2 protein overexpression is currently assessed by immunohistochemistry (IHC) and ERBB2 gene amplification by fluorescence in situ hybridization (FISH). Targeted next-generation sequencing (NGS) is increasingly used to routinely identify predictive and prognostic molecular abnormalities in endometrial carcinoma. To investigate the ability of a targeted NGS panel to detect ERBB2 amplification, we identified cases of uterine serous carcinoma (n = 93) and compared HER2 expression by IHC and copy number assessed by FISH with copy number status assessed by NGS. ERBB2 copy number status using a combination of IHC and FISH was interpreted using the 2018 ASCO/CAP guidelines for breast carcinoma. ERBB2 amplification by NGS was determined by the relative number of reads mapping to ERBB2 in tumor DNA compared to control nonneoplastic DNA. Cases with copy number ≥6 were considered amplified and copy number <6 were non-amplified. By IHC, 70 specimens were classified as negative (0 or 1+), 19 were classified as equivocal (2+), and 4 were classified as positive (3+). Using combined IHC/FISH, ERBB2 amplification was observed in 8 of 93 cases (9%). NGS identified the same 8 cases with copy number ≥6; all 85 others had copy number <6. In this series, NGS had 100% concordance with combined IHC/FISH in identifying ERBB2 amplification. NGS is highly accurate in detecting ERBB2 amplification in uterine serous carcinoma and provides an alternative to measurement by IHC and FISH.
Similar articles
-
ERBB2 amplification status in 67 salivary duct carcinomas assessed by immunohistochemistry, fluorescence in situ hybridization, and targeted exome sequencing.Mod Pathol. 2022 Jul;35(7):895-902. doi: 10.1038/s41379-021-00999-0. Epub 2021 Dec 28. Mod Pathol. 2022. PMID: 34963694 Free PMC article.
-
Next-generation assessment of human epidermal growth factor receptor 2 gene (ERBB2) amplification status in invasive breast carcinoma: a focus on Group 4 by use of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 testing guideline.Histopathology. 2021 Mar;78(4):498-507. doi: 10.1111/his.14241. Epub 2020 Oct 12. Histopathology. 2021. PMID: 32841416 Free PMC article.
-
HER2/ERBB2 copy number analysis by targeted next-generation sequencing in breast cancer.Am J Clin Pathol. 2024 May 2;161(5):436-442. doi: 10.1093/ajcp/aqad167. Am J Clin Pathol. 2024. PMID: 38104247
-
The role of HER2 as a therapeutic biomarker in gynaecological malignancy: potential for use beyond uterine serous carcinoma.Pathology. 2023 Feb;55(1):8-18. doi: 10.1016/j.pathol.2022.11.004. Epub 2022 Nov 23. Pathology. 2023. PMID: 36503635 Review.
-
HER2 in uterine serous carcinoma: Current state and clinical perspectives.Am J Clin Pathol. 2023 Oct 3;160(4):341-351. doi: 10.1093/ajcp/aqad056. Am J Clin Pathol. 2023. PMID: 37267036 Review.
Cited by
-
Narrative review on the evolving role of HER2/neu targeting in uterine serous cancers.Ann Transl Med. 2024 Aug 1;12(4):69. doi: 10.21037/atm-23-1465. Epub 2023 Nov 9. Ann Transl Med. 2024. PMID: 39118940 Free PMC article. Review.
-
Implementation of HER2 Testing in Endometrial Cancer, a Summary of Real-World Initial Experience in a Large Tertiary Cancer Center.Cancers (Basel). 2024 May 31;16(11):2100. doi: 10.3390/cancers16112100. Cancers (Basel). 2024. PMID: 38893219 Free PMC article.
-
Co-Occurring Potentially Actionable Oncogenic Drivers in Non-Small Cell Lung Cancer.Front Oncol. 2021 Jun 16;11:665484. doi: 10.3389/fonc.2021.665484. eCollection 2021. Front Oncol. 2021. PMID: 34221980 Free PMC article.
-
Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung Adenocarcinoma.J Thorac Oncol. 2022 Jun;17(6):779-792. doi: 10.1016/j.jtho.2022.02.011. Epub 2022 Mar 21. J Thorac Oncol. 2022. PMID: 35331964 Free PMC article.
-
Genomic profile of Chinese patients with endometrial carcinoma.BMC Cancer. 2023 Sep 20;23(1):888. doi: 10.1186/s12885-023-11382-4. BMC Cancer. 2023. PMID: 37730563 Free PMC article.
References
-
- Cote ML, Ruterbusch JJ, Olson SH, Lu K, Ali-Fehmi R. The growing burden of endometrial cancer: a major racial disparity affecting black women. Cancer Epidemiol Biomark Prev. 2015;24:1407–15. - DOI
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous